Glu - 4 Art: 714177-00N Rev. Date: 03-Aug-12
β–Hydroxybutyrate 6.0
14
Lactate 6.6
Maltose 13.3
Pyruvate 0.31
Salicylate 4.34
Uric Acid 1.4
Notes:
1) Acetaminophen has been shown to interfere with glucose results in the i-STAT 6+, EC8+, EC4+ and
G products, at a concentration prescribed by the CLSI guideline, 1.32 mmol/L, which represents a toxic
concentration of acetaminophen. Acetaminophen at 0.132 mmol/L, which represents the upper end of the
therapeutic concentration, has been shown not to significantly interfere with i-STAT glucose results for all
i-STAT cartridges. Acetaminophen at a test level of 1.32 mmol/L (toxic concentration) has been shown
not to significantly interfere with glucose results in the i-STAT CHEM8+ and CG8+ products.
2) Acetylcysteine has been tested at two levels; the CLSI recommended level and a concentration of
0.30 mmol/L. The latter is 3 times the peak plasma therapeutic concentration associated with treatment
to reverse acetaminophen poisoning. APOC has not identified a therapeutic condition that would lead
to levels consistent with the CLSI recommended level. Acetylcysteine at a concentration of 10.2 mmol/L
decreased i-STAT glucose results, while acetylcysteine at a concentration of 0.3 mmol/L did not signifi-
cantly interfere with i-STAT glucose results.
3) Bromide has been tested at two levels; the CLSI recommended level and a therapeutic plasma con-
centration level of 2.5 mmol/L. The latter is the peak plasma concentration associated with halothane
anesthesia, in which bromide is released. APOC has not identified a therapeutic condition that would lead
to levels consistent with the CLSI recommended level. Bromide at a concentration of 37.5 mmol/L sig-
nificantly decreased i-STAT glucose results. Bromide at a concentration of 2.5 mmol/L decreased i-STAT
glucose results by approximately 5 mg/dL on cartridges heated to 37°C (CG8+, CHEM8+) and at higher
levels on cartridges not heated to 37°C (EC8+, 6+, EC4+). Consider using the CG8+ or CHEM8+ car-
tridge when testing blood from patients undergoing halothane anesthesia.
4) Hydroxyurea is a DNA synthesis inhibitor used in the treatment of various forms of cancer, sickle cell
anemia, and HIV infection. This drug is used to treat malignancies including melanoma, metastatic ovar-
ian cancer, and chronic myelogenous leukemia. It is also used in the treatment of polycythemia vera,
thrombocythemia, and psoriasis. At typical doses ranging from 500 mg to 2 g/day, concentrations of
hydroxyurea in patients’ blood may be sustained at approximately 100 to 500 µmol/L. Higher concentra-
tions may be observed soon after dosing or at higher therapeutic doses.
5) The dependence of the i-STAT glucose with respect to pH is as follows: Values below 7.4 at 37°C
decrease results by approximately 0.9 mg/dL (0.05 mmol/L) per 0.1 pH units. Values above 7.4 at 37°C
increase results by approximately 0.8 mg/dL (0.04 mmol/L) per 0.1 pH units.
6) The dependence of the i-STAT glucose with respect to pO
2
is as follows: Oxygen levels of less than 20
mmHg (2.66 kPa) at 37°C may decrease results.
* It is possible that other interfering substance may be encountered. The degree of interference at concentrations other than those listed might not be
predictable.
To Next Page
Loading...
Need help?
General
